



10 AÑOS
COMPARTIENDO
INNOVACIÓN

Desde la edición génica hasta el diagnóstico: usos de CRISPR-Cas en biomedicina


Dr. Pereyra Bonnet Federico

INPA-CONICET-Universidad de Buenos Aires




. El Origen


. Sistema de defensa bacteriano




Cas. Sistema de defensa bacteriano



. Edición Génica






Síndrome de Treacher Collins




- ❖ Auggie Pullman es el niño de la película “Extraordinario” que tiene el síndrome de Treacher Collins.
- ❖ Es una enfermedad genética caracterizada por malformaciones craneofaciales (1/50000).
- ❖ Al día de hoy sólo se pueden corregir las malformaciones mediante cirugía reconstructiva.

Síndrome de Treacher Collins



En esta enfermedad, está mutado el gen *TCOF1* localizado en el cromosoma 5

Síndrome de Treacher Collins




“Entender el desarrollo embrionario editando el gen TCOF1 en un modelo animal puede proporcionar información útil para la comprensión de la patología y ensayar posibles tratamientos”.

- ❖ La Dra Nora Calcaterra y equipo están editando el gen *TCOF1* en un modelo animal para modelizar la enfermedad.



Potencial para tratar 6000 desórdenes genéticos... que hay en la clínica hoy? (30 ensayos clínicos)





July, Editas and Allergan
(July 2019, Mass, USA).


- ❖ Terapia en el cuerpo humano
- ❖ Ceguera hereditaria **Amaurosis congénita de Leber 10**
- ❖ Mutación en el gen CEP290 causa muerte de bastones.
- ❖ Inyección de CRISPR bajo la retina.
- ❖ Regeneración 60% en ratones, 28% en monos


. Edición Epigenética

EPIGENETICA









Editor's Choice




ORIGINAL ARTICLE

CRISPR-on system for the activation of the endogenous human INS gene FREE


C A Giménez, M Ielpi, A Mutto, L Grosembacher, P Argibay and F Pereyra-Bonne




GT advance online publication 7 April 2016; doi: 10.1038/gt.2016.26




. Tratamiento/Diagnóstico





Existen muchos sistemas CRISPR-Cas




Science

REPORTS


Cite as: J. S. Chen *et al.*, *Science*
10.1126/science.aar6245 (2018).

CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity


Janice S. Chen,^{1*} Enbo Ma,^{1*} Lucas B. Harrington,^{1*} Maria Da Costa,² Xinran Tian,³ Joel M. Palefsky,² Jennifer A. Doudna^{1,3,4,5,6†}




CRISPR Diagnostics




CRISPR Diagnostics




CRISPR Diagnostics



CRISPR Diagnostics




CRISPR Diagnostics




Actividad Colateral

CRISPR Diagnostics




Actividad Colateral

CRISPR Diagnostics




Actividad Colateral

CRISPR Diagnostics




Actividad Colateral

CRISPR Diagnostics




Actividad Colateral

CRISPR Diagnostics




Actividad Colateral

CRISPR Diagnostics




CRISPR Diagnostics




Actividad Colateral

CRISPR Diagnostics




Actividad Colateral

CRISPR Diagnostics





Actividad Colateral

CRISPR Diagnostics




CRISPR-Cas12 Diagnóstico




Actividad Colateral

Ventajas del sistema de detección



Poca purificación





BACTERIAS SUPER RESISTENTES

Existe la necesidad de identificar
la naturaleza de la resistencia
para un eficiente tratamiento.

Detección de resistencias




Figura 4. Detección de secuencias sintéticas de KPC, NDM y OXA por CRISPR. Valores a los 30 min en un lector de placas (TecanF2000) en 40 uL (límite de detección 10 picomolar).

Curti et al., *unpublish data*.





DENGUE
ZIKA
HANTAVIRUS



Detección de virus






Figura 1. Detección de secuencias sintéticas de dengue, zika y hantavirus por CRISPR. Valores a los 30 min en un lector de placas (TecamF2000) en 40 uL. En todos los casos se incluyó un paso inicial de RT (detección picomolar).

Curti et al., unpubish data.

CASPR

BIOTECH

Next generation of CRISPR diagnostics

(startup bajo normativa CONICET)
2019



El Equipo



Franco Goytia

CEO - B.Sc. Economics
Healthcare Specialization



Carla Giménez

CSO - PhD Candidate CRISPR



Federico Pereyra-Bonnet

CoFounder - BSc, PhD CRISPR
(INPA-UBA-CONICET)



Lucia Curti, BSc

Synthetic RNAs




Guillermo "Coco" Repizo

Bioinformatics - BSc PhD Microbiology
(IBR-CONICET)

Escenario


GRIDX



CONICET



Desafíos de CASPR




AUTOMATIZACIÓN

PORTABILIDAD

DIGITALIZACIÓN




AUTOMATIZACIÓN



RIT

Rochester
Institute of
Technology

We already have developed a CRISPR + Microfluidics Prototype



Results in < 30 minutes

Minimal sample preparation

Attomolar Sensitivity



Sample	Test Result (%)	Count	Category
CART 1	95.99 %	109	RI
CART 2	92.95 %	145	UTI
CART 3	77.82 %	579	AMR1
CART 4	5.6 %	736	AMR2
CART 5	41.27 %	266	AMR1
CART 6	74.69 %	130	AMR2
CART 7	66.23 %	944	RI
CART 8	26.40	135	HIV





PORTABILIDAD

- Test portable para Dengue
- Sin equipamiento
- USD 0,6/2 muestra (costo)
- >60 min
- Muestras humanas




Dr Marcos Miretti
Protocolo y CI aprobado






Tarjeta reactiva compatible con cualquier teléfono smart



POTENCIAL IMPACTO

CASPR
BIOTECH



SHERLOCK
BIOSCIENCES


 MammothBiosciences



“The CasPR Opportunity”

- 
1. Golfo Nuevo, Patagonia
 2. Volcán Lanín, Neuquén
 3. Glaciar Perito Moreno, Santa Cruz
 4. Marambio, Antartica





Muchas
Gracias

